{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:10Z","timestamp":1787387050883,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03667-4","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:23:21Z","timestamp":1782203001000},"page":"4195-4217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral and Autonomic Diabetic Neuropathy and Their Additive Risk of Major Adverse Liver Outcomes in Type\u00a02 Diabetes"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8066-9470","authenticated-orcid":false,"given":"Alex E.","family":"Henney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Isanejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Cuthbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"10397","key":"3667_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong KL, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203\u201334.","journal-title":"Lancet"},{"key":"3667_CR2","doi-asserted-by":"publisher","first-page":"112431","DOI":"10.1016\/j.diabres.2025.112431","volume":"228","author":"M Anson","year":"2025","unstructured":"Anson M, et al. The rapidly increasing incidence of type\u00a02 diabetes and macrovascular and microvascular complications disproportionately affects younger age groups: a decade of evidence from an international federated database. Diabetes Res Clin Pract. 2025;228:112431.","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"3667_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","volume":"8","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, et al. Type\u00a02 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(9):829\u201336.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"3667_CR4","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2337\/dc23-1937","volume":"47","author":"Y Shang","year":"2024","unstructured":"Shang Y, et al. Metabolic syndrome traits increase the risk of major adverse liver outcomes in type\u00a02 diabetes. Diabetes Care. 2024;47(6):978\u201385.","journal-title":"Diabetes Care"},{"issue":"7","key":"3667_CR5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057\u201382.","journal-title":"Diabetes Care"},{"issue":"5","key":"3667_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.pcd.2019.12.005","volume":"14","author":"J Sun","year":"2020","unstructured":"Sun J, et al. Prevalence of peripheral neuropathy in patients with diabetes: a systematic review and meta-analysis. Prim Care Diabetes. 2020;14(5):435\u201344.","journal-title":"Prim Care Diabetes"},{"issue":"2","key":"3667_CR7","doi-asserted-by":"publisher","first-page":"e0212574","DOI":"10.1371\/journal.pone.0212574","volume":"14","author":"X Liu","year":"2019","unstructured":"Liu X, et al. The risk factors for diabetic peripheral neuropathy: a meta-analysis. PLoS ONE. 2019;14(2):e0212574.","journal-title":"PLoS ONE"},{"key":"3667_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002480","author":"M Chowdhury","year":"2021","unstructured":"Chowdhury M, et al. Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type\u00a01 and type\u00a02 diabetes: a meta-analysis. BMJ Open Diabetes Res Care. 2021. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002480.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"3667_CR9","doi-asserted-by":"publisher","first-page":"E107","DOI":"10.1152\/ajpendo.00205.2023","volume":"326","author":"C-C Chen","year":"2024","unstructured":"Chen C-C, et al. Human liver afferent and efferent nerves revealed by 3-D\/Airyscan super-resolution imaging. Am J Physiol Endocrinol Metab. 2024;326(2):E107\u201323.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"3667_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.bbadis.2010.01.006","volume":"1802","author":"CX Yi","year":"2010","unstructured":"Yi CX, et al. The role of the autonomic nervous liver innervation in the control of energy metabolism. Biochim Biophys Acta. 2010;1802(4):416\u201331.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"3667_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/hepr.12760","volume":"47","author":"K Mizuno","year":"2017","unstructured":"Mizuno K, Ueno Y. Autonomic nervous system and the liver. Hepatol Res. 2017;47(2):160\u20135.","journal-title":"Hepatol Res"},{"issue":"3","key":"3667_CR12","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1210\/jc.2017-02294","volume":"103","author":"D Ziegler","year":"2018","unstructured":"Ziegler D, et al. Association of lower cardiovagal tone and baroreflex sensitivity with higher liver fat content early in type\u00a02 diabetes. J Clin Endocrinol Metab. 2018;103(3):1130\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"3667_CR13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.jhep.2019.01.035","volume":"70","author":"D Houghton","year":"2019","unstructured":"Houghton D, et al. The degree of hepatic steatosis associates with impaired cardiac and autonomic function. J Hepatol. 2019;70(6):1203\u201313.","journal-title":"J Hepatol"},{"issue":"1","key":"3667_CR14","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1038\/s41598-023-32115-4","volume":"13","author":"X Gu","year":"2023","unstructured":"Gu X, et al. Association between nonalcoholic fatty liver disease and peripheral neuropathy in US population, a cross-sectional study. Sci Rep. 2023;13(1):5304.","journal-title":"Sci Rep"},{"issue":"2","key":"3667_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/liv.14274","volume":"40","author":"R Lombardi","year":"2020","unstructured":"Lombardi R, et al. Liver fibrosis by FibroScan(\u00ae) independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type\u00a02 diabetes. Liver Int. 2020;40(2):347\u201354.","journal-title":"Liver Int"},{"issue":"8","key":"3667_CR16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.jdiacomp.2015.06.015","volume":"29","author":"KH Williams","year":"2015","unstructured":"Williams KH, et al. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. J Diabetes Complicat. 2015;29(8):1240\u20137.","journal-title":"J Diabetes Complicat"},{"issue":"2","key":"3667_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/joim.13673","volume":"294","author":"T Ebert","year":"2023","unstructured":"Ebert T, et al. Increased risk for microvascular outcomes in NAFLD\u2014a nationwide, population-based cohort study. J Intern Med. 2023;294(2):216\u201327.","journal-title":"J Intern Med"},{"issue":"6","key":"3667_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.pcd.2019.03.009","volume":"13","author":"M Afarideh","year":"2019","unstructured":"Afarideh M, et al. Association of non-alcoholic fatty liver disease with microvascular complications of type\u00a02 diabetes. Prim Care Diabetes. 2019;13(6):505\u201314.","journal-title":"Prim Care Diabetes"},{"issue":"3","key":"3667_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.eprac.2021.02.004","volume":"28","author":"X Wen","year":"2022","unstructured":"Wen X, et al. Association between non-alcoholic fatty liver disease and diabetes-related microvascular complications: a retrospective cross-sectional study of hospitalized patients. Endocr Pract. 2022;28(3):304\u20139.","journal-title":"Endocr Pract"},{"issue":"11","key":"3667_CR20","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1111\/liv.16086","volume":"44","author":"AE Henney","year":"2024","unstructured":"Henney AE, et al. Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD. Liver Int. 2024;44(11):3031\u201349.","journal-title":"Liver Int"},{"key":"3667_CR21","doi-asserted-by":"publisher","first-page":"752944","DOI":"10.3389\/fendo.2021.752944","volume":"12","author":"I Jung","year":"2021","unstructured":"Jung I, et al. Autonomic imbalance increases the risk for non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2021;12:752944.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"17","key":"3667_CR22","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1113\/JP277994","volume":"597","author":"C Hurr","year":"2019","unstructured":"Hurr C, et al. Liver sympathetic denervation reverses obesity-induced hepatic steatosis. J Physiol. 2019;597(17):4565\u201380.","journal-title":"J Physiol"},{"key":"3667_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fphys.2012.00010","volume":"3","author":"MP Schlaich","year":"2012","unstructured":"Schlaich MP, et al. Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Front Physiol. 2012;3:10.","journal-title":"Front Physiol"},{"issue":"6","key":"3667_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/ehjqcco\/qcac056","volume":"9","author":"RE Schmieder","year":"2023","unstructured":"Schmieder RE, et al. Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry. Eur Heart J Qual Care Clin Outcomes. 2023;9(6):575\u201382.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"7","key":"3667_CR25","doi-asserted-by":"publisher","first-page":"e17591","DOI":"10.1016\/j.heliyon.2023.e17591","volume":"9","author":"JQ Gao","year":"2023","unstructured":"Gao JQ, et al. Effects of renal denervation on cardiac function after percutaneous coronary intervention in patients with acute myocardial infarction. Heliyon. 2023;9(7):e17591.","journal-title":"Heliyon"},{"issue":"4","key":"3667_CR26","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.clnu.2021.02.027","volume":"40","author":"AK Miroslawska","year":"2021","unstructured":"Miroslawska AK, et al. Metabolic effects two years after renal denervation in insulin resistant hypertensive patients. The Re-Shape CV-risk study. Clin Nutr. 2021;40(4):1503\u20139.","journal-title":"Clin Nutr"},{"issue":"7","key":"3667_CR27","doi-asserted-by":"publisher","first-page":"p. sfaf184","DOI":"10.1093\/ckj\/sfaf184","volume":"18","author":"V Bytyqi","year":"2025","unstructured":"Bytyqi V, et al. Effect of renal denervation on glucose metabolism in hypertensive patients with and without chronic kidney disease. Clin Kidney J. 2025;18(7):sfaf184.","journal-title":"Clin Kidney J"},{"key":"3667_CR28","doi-asserted-by":"publisher","first-page":"6915310","DOI":"10.1155\/2017\/6915310","volume":"2017","author":"U Kampmann","year":"2017","unstructured":"Kampmann U, et al. Effects of renal denervation on insulin sensitivity and inflammatory markers in nondiabetic patients with treatment-resistant hypertension. J Diabetes Res. 2017;2017:6915310.","journal-title":"J Diabetes Res"},{"issue":"18","key":"3667_CR29","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1161\/CIRCULATIONAHA.110.991869","volume":"123","author":"F Mahfoud","year":"2011","unstructured":"Mahfoud F, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123(18):1940\u20136.","journal-title":"Circulation"},{"issue":"2","key":"3667_CR30","doi-asserted-by":"publisher","first-page":"p.ooad035","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6(2):p.ooad035.","journal-title":"JAMIA Open"},{"issue":"1","key":"3667_CR31","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1186\/s12916-024-03802-4","volume":"22","author":"M Anson","year":"2024","unstructured":"Anson M, et al. The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study. BMC Med. 2024;22(1):574.","journal-title":"BMC Med"},{"issue":"4","key":"3667_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"7624","key":"3667_CR33","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E Elm","year":"2007","unstructured":"Elm E, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806.","journal-title":"BMJ"},{"key":"3667_CR34","doi-asserted-by":"publisher","first-page":"156306","DOI":"10.1016\/j.metabol.2025.156306","volume":"170","author":"DJ Cuthbertson","year":"2025","unstructured":"Cuthbertson DJ, et al. Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes. Metabol Clin Exp. 2025;170:156306.","journal-title":"Metabol Clin Exp"},{"issue":"1","key":"3667_CR35","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41598-025-31797-2","volume":"16","author":"M Poorrezaei","year":"2025","unstructured":"Poorrezaei M, et al. Associations between peripheral neuropathy and cardiovascular complications in patients with type\u00a02 diabetes mellitus: a cross-sectional study. Sci Rep. 2025;16(1):2129.","journal-title":"Sci Rep"},{"issue":"23","key":"3667_CR36","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1136\/heartjnl-2014-305657","volume":"100","author":"JRW Brownrigg","year":"2014","unstructured":"Brownrigg JRW, et al. Peripheral neuropathy and the risk of cardiovascular events in type\u00a02 diabetes mellitus. Heart. 2014;100(23):1837.","journal-title":"Heart"},{"issue":"1","key":"3667_CR37","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41598-022-05037-w","volume":"12","author":"IY Choi","year":"2022","unstructured":"Choi IY, et al. Low heart rate variability from 10-s electrocardiograms is associated with development of non-alcoholic fatty liver disease. Sci Rep. 2022;12(1):1062.","journal-title":"Sci Rep"},{"issue":"1","key":"3667_CR38","doi-asserted-by":"publisher","first-page":"24372","DOI":"10.1038\/s41598-021-03870-z","volume":"11","author":"K Kim","year":"2021","unstructured":"Kim K, et al. Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type\u00a02 diabetes. Sci Rep. 2021;11(1):24372.","journal-title":"Sci Rep"},{"key":"3667_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-026-01633-y","author":"WY Poh","year":"2026","unstructured":"Poh WY, et al. Improving stratification of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease patients with type-2 diabetes mellitus in low-resource settings. Int J Diabet Dev Countr. 2026. https:\/\/doi.org\/10.1007\/s13410-026-01633-y.","journal-title":"Int J Diabet Dev Countr"},{"key":"3667_CR40","doi-asserted-by":"publisher","first-page":"103489","DOI":"10.1016\/j.eclinm.2025.103489","volume":"89","author":"AE Henney","year":"2025","unstructured":"Henney AE, et al. Spinal cord stimulation for the treatment of painful diabetic neuropathy and risk of major adverse cardiovascular events, mortality, amputation, infection and suicide: a retrospective cohort study. EClinicalMedicine. 2025;89:103489.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"3667_CR41","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s00125-024-06242-0","volume":"67","author":"A Eleftheriadou","year":"2024","unstructured":"Eleftheriadou A, et al. Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management. Diabetologia. 2024;67(12):2611\u201325.","journal-title":"Diabetologia"},{"issue":"1","key":"3667_CR42","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","volume":"40","author":"R Pop-Busui","year":"2017","unstructured":"Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136\u201354.","journal-title":"Diabetes Care"},{"issue":"2","key":"3667_CR43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/jama.293.2.217","volume":"293","author":"N Singh","year":"2005","unstructured":"Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217\u201328.","journal-title":"JAMA"},{"issue":"1","key":"3667_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0953-6205(00)00128-X","volume":"12","author":"N Tentolouris","year":"2001","unstructured":"Tentolouris N, Pagoni S, Tzonou A, Katsilambros N. Peripheral neuropathy does not invariably coexist with autonomic neuropathy in diabetes mellitus. Eur J Intern Med. 2001;12(1):20\u20137.","journal-title":"Eur J Intern Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03667-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03667-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03667-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:33Z","timestamp":1787385873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03667-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3667"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03667-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Daniel J Cuthbertson has received investigator-initiated grants from Astra Zeneca and Novo Nordisk, support for education from Perspectum and consultancy fees from Madrigal with any financial remuneration from pharmaceutical company consultation made to the University of Liverpool. Daniel J Cuthbertson also serves as the Topic Advisor for Type\u00a02 Diabetes medications for The National Institute for Health and Care Excellence (NICE), UK. Uazman Alam declare she has received honoraria from Eli Lilly, Procter & Gamble, Viatris, Grunenthal, Theras and Sanofi for educational meetings and funding for attendance to an educational meeting from Diiachi Sankyo. UA has also received investigator-led funding by Procter & Gamble, GSK and Axonis Therapeutics and is a council member of the Royal Society of Medicine\u2019s Vascular, Lipid & Metabolic Medicine Section. UA is supported by the National Institute for Health Research Applied Research Collaboration North West Coast (ARC NWC). The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. All other authors (Alex E Henney, Masoud Isanejad) have no conflicts to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study is exempt from informed consent. The data reviewed is a secondary analysis of existing data, does not involve intervention or interaction with human subjects, and is de-identified per the de-identification standard defined in Section \u00a7164.514(a) of the HIPAA Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in Section \u00a7164.514(b)(1) of the HIPAA Privacy Rule. This formal determination by a qualified expert refreshed on December 2020.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}